We are live on ! Find out more
PRHC

P.R. Herzig & Co Portfolio holdings

AUM $45.9M
1-Year Est. Return 15.88%
This Fund
S&P 500
This Quarter Est. Return
-9.15%
1 Year Est. Return
+15.88%
3 Year Est. Return
+49.95%
5 Year Est. Return
+89.91%
10 Year Est. Return
–
AUM
$39.9M
AUM Growth
-$9.54M
Cap. Flow
-$4.44M
Cap. Flow %
-11.12%
Top 10 Hldgs %
46.27%
Holding
51
New
5
Increased
8
Reduced
16
Closed
7

Top Buys

Rank Stock Value
1
URI icon
United Rentals
URI
+$600K
2
IBM icon
IBM
IBM
+$449K
3
AMGN icon
Amgen
AMGN
+$394K
4
ECL icon
Ecolab
ECL
+$336K
5
CAFD
8point3 Energy Partners LP
CAFD
+$335K

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$1.6M
2
NVDA icon
NVIDIA
NVDA
+$1.26M
3
INTC icon
Intel
INTC
+$1.06M
4
ORCL icon
Oracle
ORCL
+$576K
5
FSLR icon
First Solar
FSLR
+$409K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 21%
2 Technology 18.42%
3 Industrials 15.14%
4 Healthcare 9%
5 Miscellaneous 7.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYK icon
26
Stryker
SYK
$124B
$687K 1.72%
7,300
– –
NKE icon
27
Nike
NKE
$57B
$590K 1.48%
9,600
– –
SBUX icon
28
Starbucks
SBUX
$122B
$563K 1.41%
9,900
+2,900
+41% +$162K
BKNG icon
29
Booking.com
BKNG
$152B
$550K 1.38%
11,125
– –
CEF icon
30
Sprott Physical Gold and Silver Trust
CEF
$8.31B
$542K 1.36%
51,200
– –
NEM icon
31
Newmont
NEM
$139B
$530K 1.33%
33,000
-500
-1% -$8.95K
FNF icon
32
Fidelity National Financial
FNF
$12.7B
$444K 1.11%
18,048
-5,042
-22% -$132K
IBM icon
33
IBM
IBM
$225B
$422K 1.06%
+3,044
New +$449K
BMY icon
34
Bristol-Myers Squibb
BMY
$137B
$399K 1%
6,738
-2,899
-30% -$184K
SLB icon
35
SLB Ltd
SLB
$81.6B
$372K 0.93%
5,400
-2,300
-30% -$182K
AMGN icon
36
Amgen
AMGN
$236B
$346K 0.87%
+2,500
New +$394K
ECL icon
37
Ecolab
ECL
$80.1B
$329K 0.82%
+3,000
New +$336K
JNJ icon
38
Johnson & Johnson
JNJ
$640B
$299K 0.75%
3,200
-500
-14% -$48.4K
SUNE
39
DELISTED
SUNEDISON, INC COM
SUNE
$287K 0.72%
40,000
+1,000
+3% +$17.9K
SPY icon
40
State Street SPDR S&P 500 ETF Trust
SPY
$827B
$283K 0.71%
1,475
+25
+2% +$5.07K
CAFD
41
DELISTED
8point3 Energy Partners LP
CAFD
$233K 0.58%
+22,000
New +$335K
CLD
42
DELISTED
Cloud Peak Energy Inc
CLD
$187K 0.47%
71,100
-7,500
-10% -$25K
EMAN
43
DELISTED
eMagin Corporation
EMAN
$48K 0.12%
20,000
– –
GSS
44
DELISTED
Golden Star Resources Ltd.
GSS
$3K 0.01%
+3,000
New +$3.39K
FSLR icon
45
First Solar
FSLR
$22.6B
– –
-8,700
Closed -$409K
INTC icon
46
Intel
INTC
$487B
– –
-34,900
Closed -$1.06M
NVDA icon
47
NVIDIA
NVDA
$5.52T
– –
-2,501,360
Closed -$1.26M
NVO
48
Novo Nordisk
NVO
$205B
– –
-12,400
Closed -$340K
ORCL icon
49
Oracle
ORCL
$438B
– –
-14,300
Closed -$576K
TEVA icon
50
Teva Pharmaceuticals
TEVA
$43.8B
– –
-27,100
Closed -$1.6M
1
2
3

Similar funds

NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
AVA
Accel VIII Associates Palo Alto, California $65.1M AUM
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return

P.R. Herzig & Co's Q3 2015 Portfolio in Review

As of Q3 2015, P.R. Herzig & Co held 51 positions worth $39.9M, down 19% from $49.4M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

P.R. Herzig & Co withdrew a net $4.44M in Q3 2015, closing 7 positions and reducing 16 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $1.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 21% of assets, up from 18% a quarter earlier, followed by Technology and Industrials.

Against the trend, P.R. Herzig & Co opened a new position in IBM worth $422K.

  • P.R. Herzig & Co's largest Q3 2015 buy was IBM: 3,044 shares worth $422K.
  • P.R. Herzig & Co added most to United Rentals in Q3 2015, an estimated $600K increase.
  • P.R. Herzig & Co's biggest Q3 2015 reduction was PTC, cutting an estimated $351K.
  • P.R. Herzig & Co fully exited Teva Pharmaceuticals in Q3 2015, selling an estimated $1.6M.
  • P.R. Herzig & Co's ten largest holdings make up 46% of its $39.9M portfolio in Q3 2015.
  • P.R. Herzig & Co opened 5 new positions and closed 7 in Q3 2015.
  • P.R. Herzig & Co's portfolio value fell 19% quarter-over-quarter to $39.9M.

Based on P.R. Herzig & Co's 13F filing for Q3 2015, filed 19 Oct 2015.